Redefining ‘First‑in‑Class’ Amid Faster Competing Therapies
How do we define “first in class” when there are others further ahead? This example is from Atheron Therapeutics w/ a CCNE1 degrader #aacr26 https://t.co/s22biREUrt
Nurix's NRX-0305 Shows
New degrader from Nurix looks interesting: NRX-0305 demonstrated antitumour activity across a wide range of Class 1 BRAF inhibitor-resistant and Class 2/3 mutant PDX models #aacr26 https://t.co/0UGF5Od2Cp
Daraxonrasib Monotherapy
Eileen O’Reilly’s daraxonrasib monoTx data in 1L PDAC - poster below to save y’all fighting through rows of people to get a view #aacr26 https://t.co/z4yW2apCBf
Avacta Unveils FAP‑cleavable Dual TOPO‑Ii/DDR‑i Payload
Intriguing #AACR26 poster from Avacta w/ CSO Francis Wilson presenting on their dual payload tech. The idea is to release TOPO-Ii + DDRi via FAP cleavage https://t.co/UMeB8y8KaC
ARVN KRAS G12D Preclinical Shows Weak Tumor Inhibition
In the battle of the inhibitors vs glues vs degraders, this one (KRAS G12D preclinical) from ARVN doesn't look too encouraging with little TGI #aacr26 https://t.co/Ng9UWTQcsv
Four Overlooked AACR Early-Stage Agents Worth Watching
While everyone was watching KRAS, some of AACR’s promising early stage pipeline agents were easy to miss. Here's an analysis on four examples which caught my eye and are well worth watching to see how they develop in the...
Unexpected Insight Among 11 Lessons From AACR26
11 things I learned at #AACR26 Industry Partnering event – number 7 may well surprise you: https://t.co/T0ePbaIU1K https://t.co/CMh15HfnnG
Amgen's Potts Lab Unveils Universal Molecular Glue Platform
Next up #aacr26 is @pottslab from Amgen discussing their broad and diverse molecular glue & degrader platform “any target, every time” https://t.co/SfJ0jGYene
DepMap's Future: PRMT5 Inhibitor Differences Unveiled
Excellent talk from Bill Sellers on future directions with DepMap. Interesting differences between different PRMT5 inhibitors (SAM & MTA) and how they compare with selective inhibitors #aacr26 https://t.co/xfmKVqEpp1
AI Maps Tumors in 3D Single‑cell Detail for Early Detection
For anyone w/ access to #AACR26 recordings and interested in early cancer detection, @deniswirtz gave a beautiful talk yesterday on AI-driven mapping of tumours in 3D and at single-cell resolution. Two examples from the pancreas and fallopian tubes: https://t.co/sLXh5FX6du
SGO Numbers: Some Winners, Many Disappointments Await
Lots of gaudy headline numbers coming out of SGO this year; do they stack up under scrutiny? My take – some winners likely and many tears before bedtime for others. Which ones fall in the latter category? ...
REPL RP1 Melanoma Trial Flawed; New CRL
I've never covered the REPL RP1 data in melanoma, mainly due to dislike of the trial design w/ its lack of a monotherapy arm. Sometimes you can see where things are likely headed and kicking a dog when it's down...
New Cytotoxic Targets Unveiled at AACR26
Time to head off the beaten track at #AACR26 with our latest preview exploring novel targets and cytotoxics. The long climb up the hill may be worth it for some of them: https://t.co/l9tkdWvpuF https://t.co/M5B3RTW1wf
Myeloma Survival Breakthrough: Two Decades After Dalton’s Wish
I remember interviewing Bill Dalton in 2005 about new developments in myeloma and how he wished for new regimens to take OS out beyond 3-4 yrs. Two decades on we've hit jackpot...
New Early-Stage Cancer Drugs Emerge at AACR26
A look at some promising early stage drug developments coming down the pike at #AACR26. A few of these concepts were not on the radar a couple of years ago: https://t.co/w6oD4CEckq https://t.co/kfR1AXG41K
Setidegrasib’s KRAS Degradation Still Unproven in Cancer
Elegant in theory, unproven in practice: setidegrasib and the case (or not) for KRAS degradation in NSCLC and pancreatic cancer: https://t.co/NuaOJ2amgn https://t.co/i9FpK4W19W
CytomX CRC Data Demand Double‑Take, Not Clear Verdict
Some clinical updates tell you exactly what they are. Others ask to be read twice. CytomX’s latest CRC data belong firmly in the second category. Is the die cast? https://t.co/dfdPxx4zXs https://t.co/y9QAoahMut
Emerging KRAS Combo Therapies Show Promising Progress
The KRAS niche has been a deluge of new selective and pan/multi inhibitors. Now there are combos to watch out for – we may be making progress. Here are insights on 7 of them: https://t.co/F9HmM8A4ud https://t.co/IqWw6n2m3k
Bladder Cancer Landscape Shifts, Opening New Strategic Opportunities
When cancer niches are rapidly changing they create both a vacuum of indecision and fresh opportunities for smart players. Here we explore bladder cancer and look at where the field is headed... https://t.co/cf93Qb8dhe https://t.co/fx5V1MVwYN
Comparing Lorigerlimab, Volrustomig, Cadonilimab: Design Lessons
An intriguing tale of three cities. How do the PD1xCTLA4 bispecific agents lorigerlimab, volrustomig, and cadonilimab stack up when it comes to design and performance? Some useful and pointed lessons here for biotech execs: https://t.co/xaSW15Fvdl https://t.co/dhXbiI3N6v
Emerging Protein Degradation Trends and CAR‑T Synergies
What gets missed in the hurly burly of a conference with many highlight reels? Here we explore emerging trends to watch out for when it comes to protein degradation/glues, & combination opportunities w/ CAR-T cells. Time for some...
Key Differences Between Anti‑cel and Cilta‑cel Explain GILD Deal
By chance I was writing about anito-cel vs. cilta-cel on Friday, not knowing $GILD acquisition was coming down the pike. There are some crucial differences between the two products to take note of, which may explain why they were...
European ADC Agents with Novel Targets Gain Momentum
With all the attention on China for TOPO-I ADCs of late, how about the potential for European agents, especially ones involving novel targets? Our latest expert interview drops with some hard hitting and candid opinions from a battle hardened...
Zanidatamab Gastric Cancer Data Faces Seven Bearish Concerns
It's good to see new trial readouts at #GI26, although there are 7 reasons to be bearish about the zanidatamab data in gastric cancer: https://t.co/g2MbrPI7Iu https://t.co/tBY2yJ6YMe
Zanidatamab Plus Tislelizumab Raises Diarrhea Risk
#GI26 zanidatamab/chemo ± tislelizumab in the HERIZON-GEA-01 trial: not much attention on side effect profile. If you combine zani, tisle and 5FU you will get more diarrhea/discontinuations https://t.co/55aDi7Pnpx